日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database

在非 2 型糖尿病患者中,替泽帕肽的真实世界使用情况和疗效:来自 Optum Market Clarity 数据库的结果

Hankosky, Emily R; Chinthammit, Chanadda; Meeks, Alexandra; Huang, Ahong; Ward, Jennifer M; Mojdami, Donna; Gibble, Theresa Hunter

Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database

在无 2 型糖尿病证据的个体中实际使用替泽帕肽:来自 Veradigm® 数据库的结果

Hunter Gibble, Theresa; Chinthammit, Chanadda; Ward, Jennifer M; Cappell, Katherine; Sedgley, Robert; Bonafede, Machaon; Liao, Birong; Hankosky, Emily R

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison

在肥胖或超重且患有 2 型糖尿病的患者中,替拉帕肽 10 毫克和 15 毫克与司美格鲁肽 2.4 毫克的疗效比较:一项间接治疗比较研究

Hankosky, Emily R; He, Xuanyao; Malik, Raleigh; Fraseur Brumm, Julia; Wang, Fangyu; Niemeyer, Anthony; Zhang, Xiaotian M; Garvey, W Timothy

Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial

替拉帕肽与肥胖和糖尿病前期成人10年心血管疾病和2型糖尿病预测风险:一项来自为期三年的SURMOUNT-1试验的事后分析

Hankosky, Emily R; Lebrec, Jeremie; Lee, Clare J; Dimitriadis, Georgios K; Jouravskaya, Irina; Stefanski, Adam; Garvey, W Timothy

Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity

对超重和肥胖患者,采用替泽帕肽与生活方式干预相比,进行潜在成本效益建模分析

Hoog, Meredith M; Kan, Hong; Deger, Kristen A; Sorensen, Sonja; Neff, Lisa M; Bae, Jay Patrick; Hankosky, Emily Ruth; Murphy, Madhumita; Mojdami, Donna; Houisse, Ivan; Harris, Mack S

Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence

替拉帕肽与肥胖症患者的心血管代谢参数:现有证据总结

Sattar, Naveed; García-Pérez, Luis-Emilio; Rodríguez, Angel; Kapoor, Richa; Stefanski, Adam; Hankosky, Emily R

Gaps Remain for Achieving HbA1c Targets for People with Type 1 or Type 2 Diabetes Using Insulin: Results from NHANES 2009-2020

使用胰岛素治疗1型或2型糖尿病患者达到HbA1c目标仍存在差距:2009-2020年NHANES调查结果

Hankosky, Emily R; Schapiro, David; Gunn, Karli B; Lubelczyk, Elizabeth B; Mitroi, Jessica; Nelson, David R

The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes

从糖尿病患者的角度看餐时胰岛素的负担和影响

Paczkowski, R; Poon, J L; Cutts, K N; Krucien, N; Osumili, B; de Oliveira, C Piras; Hankosky, E R; Perez-Nieves, M; Radawski, C; Gelhorn, H L

The experience of a severe hypoglycaemic event from the perspective of people with diabetes and their caregivers: "What am I going to do?"

从糖尿病患者及其护理人员的角度来看,发生严重低血糖事件的体验是:“我该怎么办?”

Stuckey, Heather L; Desai, Urvi; King, Sarah B; Popadic, Lyuba; Levinson, William; Kirson, Noam Y; Hankosky, Emily R; Mitchell, Beth

Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States

与新冠肺炎住院和死亡相关的风险因素:一项基于美国2型糖尿病患者的大型索赔数据分析

Boye, Kristina S; Tokar Erdemir, Elif; Zimmerman, Nathan; Reddy, Abraham; Benneyworth, Brian D; Dabora, Matan C; Hankosky, Emily R; Bethel, M Angelyn; Clark, Callahan; Lensing, Cody J; Sailer, Scott; San Juan, Ramira; Heine, Robert J; Etemad, Lida